What's the fastest, lowest-risk route to an approved drug? Develop somebody else's clinical-stage therapeutic. But finding them is tough--and to get a reasonable return on investment, the in-licensor needs to bring value the originator couldn't.
by Roger Longman
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
